A late-stage trial of a combination of an experimental cancer-fighting drug from Genentech and the already-marketed drug Tarceva didn’t help patients with a type of advanced lung cancer live longer.An independent data monitoring committee recommended that the 499-patient, Phase III study of onartuzumab and Tarceva be stopped, South San Francisco-based Genentech said Sunday night. The study indicated that the combination did not help previously treated advanced non-small cell lung cancer patients live longer than those treated with only Tarceva.
From here: http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/03/genentech-onartuzumab-roche-lung-cancer.html
No comments:
Post a Comment